Back to companies
Everalbum, Inc.
Seed / Series Adefense-other · Series A
Seed Signal Score
12/25
Team Strength
2/5
Validation Depth
3/5
Novelty
2/5
Market Timing
3/5
Capital Efficiency
2/5
Funding
$3.3M
Total raised
$3.3M
Last round · May 13, 2022
Description
PLASMA TACFI Phase IIB
Validation Signals
SBIR Phase II
Score Rationale
Everalbum shows modest validation through SBIR Phase II funding but lacks named founder information and verifiable defense expertise, constraining team strength. The company's positioning as 'defense-other' with limited public detail on PLASMA TACFI differentiation, combined with $3.3M raised against unclear product shipping metrics, suggests incremental progress in a potentially crowded space without compelling evidence of capital efficiency or technical novelty.